Some solid tumors are what oncologists call "immune cold": the immune system simply cannot see them. George Sens puts that at 90 to 95 percent of MSS colorectal cases, and notes five-year survival under 13 percent for pancreatic. His framing, borrowed from a doctor he heard it from: your first and last line of defense is your immune system. For these tumors, it is flying blind.

LurexBio sits upstream of the therapies you see advertised. Rather than replacing or boosting the immune system, its platform is designed to make cold tumors visible to it — and to do that non-genetically. George's analogy on the episode: the immune system is an airplane, the cold tumor is a pitch-black runway, and the company's job is to put the lights up so the plane can land.

The company came out of founder James Clark's own diagnosis. A layperson, not a physician, he was told he had stage IV prostate cancer, taught himself the immunology, and was startled to find nobody working the problem from this angle. He is still battling it, in the present tense. George came from revenue leadership in enterprise software, fintech and automotive, and describes his own job as building the company around the science.

Host Jonathan W. Buckley of The Artesian Network and George get into:

• What "immune cold" actually means, and why making a tumor visible has to come before treating it
• Evasion versus exclusion — two separate tumor problems, and which one the platform is aimed at
• Why the approach is deliberately non-genetic, and the "CSI effect" in medicine that makes everything default to DNA and mRNA
• What the company looked like when he arrived: science heavy, operationally skinny
• Standing up governance, a board and an advisory board before switching on named lab partnerships, not after
• Why this is not a software company: no MVP, no recurring revenue, and a near-term goal of proving the scientific thesis through preclinical
• The fundraising math that catches tech operators off guard — biotech seed rounds of three and a half to five million, A rounds of twenty-five to seventy-five
• Where the moat lives when you are not patenting a compound: a portfolio he puts at 27 provisional filings covering delivery and membrane attachment
• Why he argues the novel part is the combination of already-proven science, not a single new discovery
• The switch from selling businesses an improvement to working on something meant to make people's lives better

Connect with George
LinkedIn: linkedin.com/in/georgesens
LurexBio: lurexbio.com

Follow the show
YouTube: youtube.com/@theartesiannetwork
Spotify: open.spotify.com
Apple Podcasts: podcasts.apple.com

Every episode, on every platform: WeBuiltItBecauseWeHadTo.com

More from The Artesian Network: artesiannetwork.com